is a PhD molecular cytogeneticist with over 20yrs experience in molecular diagnostics. After working at the Institute of Cancer Research in the ‘90’s he moved to a number of companies in the diagnostics field, firstly MWG Biotech then Tecan before joining BlueGnome in 2006.
In 2008 Dr Gordon started the 24sure product line within BlueGnome, aiming to bring BlueGnome’s copy number microarray expertise to pre-implantation genetic screening (PGS). The vast majority of global PGS is preformed using 24sure/VeriSeq PGS and in 2012 BlueGnome was sold to Illumina.
After briefly working for Illumina, in 2013 Dr Gordon joined Genesis Genetics, a leading global company for PGD and PGS where he was the Managing Director for the five Genesis Genetics USA laboratories, plus Laboratory Director for Genesis Genetics two UK laboratories. In 2015 Dr Gordon started the Genesis Serenity NIPT program. In April 2016 Genesis Genetics laboratories were sold to Cooper Surgical Industries (USA).
Dr Gordon is currently the Direct of Clinical Operations for Cooper Genomics UK labs and is leading the Cooper Genomics global business development (outside the US).
Dr Gordon is also a UK State Registered Clinical scientist and is a Fellow of the Royal Society of Biology.